Enveric Biosciences, Inc. (ENVB) — Financial statements
Income statement, balance sheet, and cash flow for Enveric Biosciences, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 0.20↓40.5% | 0.34↓17.3% | 0.41↓6.2% | 0.44↓36.2% | 0.68 | |
| Gross Profit | -0.20↑40.5% | -0.34↑17.3% | -0.41↑6.2% | -0.44↑36.2% | -0.68 | |
| Operating Expenses | ||||||
| R&D Expenses | 3↓2.1% | 3↓60.8% | 7↓9.7% | 8↑67.6% | 5 | |
| General & Administrative Expenses | 6 | 0.00↓100.0% | 9 | 0.00 | 0.00 | |
| Selling & Marketing Expenses | 0.00 | 0.00↑100.0% | -0.06 | 0.00 | 0.00 | |
| SG&A Expenses | 6↓10.2% | 6↓26.6% | 9↓23.6% | 11↓43.8% | 20 | |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 9↓7.8% | 9↓42.1% | 16↓17.9% | 20↓22.7% | 25 | |
| Total Costs & Expenses | 9↓8.9% | 10↓41.4% | 16↓17.6% | 20↓23.1% | 26 | |
| Operating Results | ||||||
| Operating Income | -9↑8.9% | -10↑41.4% | -16↑17.6% | -20↑23.1% | -26 | |
| Depreciation & Amortization | 0.20↓40.5% | 0.34↓17.3% | 0.41↓6.2% | 0.44↓36.2% | 0.68 | |
| EBITDA | -9↑7.1% | -9↑45.2% | -17↑13.6% | -20↑65.0% | -56 | |
| EBIT | -9↑8.3% | -10↑44.6% | -17↑13.5% | -20↑64.6% | -56 | |
| Interest & Other Income | ||||||
| Net Interest Income | -0.00↓148.4% | 0.00↑105.9% | -0.00↑29.3% | -0.01↑49.1% | -0.01 | |
| Interest Income | 0.00↓100.0% | 0.00 | 0.00↓100.0% | 0.00↓49.2% | 0.00 | |
| Interest Expense | 0.00 | 0.00↓100.0% | 0.00↓29.4% | 0.01↓49.1% | 0.01 | |
| Non-Operating Income | 0.00↑100.0% | -0.07↓108.1% | 0.81↑8856.8% | -0.01↓100.0% | 30 | |
| Other Income / Expenses | 0.00↓96.3% | 0.07↑108.1% | -0.81↓20203.2% | 0.00↑100.0% | -30 | |
| Income Before Tax | -9↑8.3% | -10↑44.6% | -17↑13.5% | -20↑64.6% | -56 | |
| Income Tax Expense | 3↑37520.2% | 0.01↓69.1% | 0.03↑101.9% | -1↑80.1% | -7 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -12↓26.7% | -10↑44.6% | -17↑6.4% | -18↑62.3% | -49 | |
| Net Income from Discontinued Operations | 0.00 | 0.00↓100.0% | 0.02 | 0.00 | 0.00 | |
| Net Income | -12↓26.7% | -10↓55273.2% | -0.02↑99.9% | -19↑62.2% | -49 | |
| Bottom-Line Net Income | -12↓26.7% | -10↑45.2% | -17↑7.1% | -19↑61.6% | -49 | |
| EPS (Basic) | -36.24↑84.1% | -228.48↓135.4% | -97.08↓10.7% | -87.72↑93.0% | -1,244.28 | |
| EPS (Diluted) | -36.24↑84.1% | -228.48↓135.4% | -97.08↑37.8% | -156.00↑87.5% | -1,244.28 | |
| Weighted Average Shares | 0.33↑698.7% | 0.04↓80.1% | 0.21↑0.0% | 0.21↑435.1% | 0.04 | |
| Weighted Average Diluted Shares | 0.33↑698.7% | 0.04↓76.7% | 0.18↑3.9% | 0.17↑340.0% | 0.04 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.